VoxCell Joins 3Rs Collaborative to Reduce Reliance on Animal Models
- VoxCell BioInnovation
- Mar 4
- 2 min read
Updated: Jul 21
Victoria, March 2025—VoxCell BioInnovation is proud to announce that we have joined the 3Rs Collaborative (3RsC) Microphysiological Systems (MPS) Initiative, a global collective effort to promote the development, adoption, and regulatory acceptance of advanced in vitro models and reduce reliance on animal testing in research.
The MPS Initiative is rooted in the 3Rs principles of Refinement, Reduction, and Replacement of animals in research. By contributing our 3D bioprinted vascularized tissue models to this community, we’re helping shape a future in which more predictive and human-relevant models replace traditional animal-based methods in drug development.
What Are Microphysiological Systems (MPS)?
MPS are sophisticated in vitro systems that emulate the structure and function of human organs and tissues. These models, which include organoids, spheroids, explants, and organ-on-a-chip technologies, are built from human or animal-derived components and can generate biochemical, electrical, and mechanical responses that mirror physiological behavior. The adoption of MPS has grown rapidly across pharmaceutical R&D, offering researchers improved predictivity for human responses, reduced reliance on animal models, and deeper insight into complex biological mechanisms.
VoxCell's 3D VASCULARIZED MODELS JOIN THE MPS MOVEMENT
VoxCell BioInnovation brings to the MPS Initiative a powerful platform for replicating human biology: vascularized 3D bioprinted tissue models that are perfusion-ready, easy to use, and engineered for disease modeling, vascular toxicity testing, and drug screening.
Our models mimic human tissues' structural and functional complexity, including tumor architecture and vasculature, enabling more predictive and human-relevant research outcomes.
By joining the MPS Initiative, we’re proud to stand alongside global leaders advancing non-animal technologies (NATs) and accelerating their validation and regulatory acceptance.
About VoxCell BioInnovation
VoxCell BioInnovation is a leading provider of next-generation in vitro models, powered by our 3D bioprinted, vascularized tissue technology. Our ready-to-perfuse models closely replicate human biology with in vivo–like microvascular networks, enabling nutrient and oxygen delivery, systemic drug distribution, and more predictive therapeutic responses. VoxCell’s end-to-end solution offers researchers and pharmaceutical companies a scalable, ethical alternative to animal testing. Our mission is to reduce reliance on animal models, accelerate preclinical development, and advance more effective therapies for patients.
Want to learn more or collaborate?
Visit our website, connect with us on LinkedIn, or email us at hello@voxcellbio.com.
